ArticleInfection2022
Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.
Article in Infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04392388 (Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis - Serology), which is not on this map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis - Serology
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Differential COVID-19 infection rates in children, adults, and elderly: Systematic review and meta-analysis of 38 pre-vaccination national seroprevalence studies.Journal of global health · 2023Pooled it
- Age-stratified infection fatality rate of COVID-19 in the non-elderly population.Environmental research · 2023Pooled it
- ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.Scientific reports · 2023Trial
- CONSTANCES, the French nationwide population cohort: major accomplishments.European journal of epidemiology · 2026Article
- Serological profile of naïve patients affected by the first sars-cov-2 variant: A prospective study.PloS one · 2026Article
- Dealing with differential misclassification of an outcome or a covariate in association studies with an internally validated sample selected not at random.BMC medical research methodology · 2025Article
- Household exposure, demographic and health characteristics associated with SARS-CoV-2 infection in a cohort study in Northern France.Scientific reports · 2025Article
- Revisiting the link between COVID-19 incidence and infection fatality rate during the first pandemic wave.Scientific reports · 2025Article
- Estimating SARS-CoV-2 infection probabilities with serological data and a Bayesian mixture model.Scientific reports · 2024Article
- Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population.Scientific reports · 2022Article
- A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project.Nature medicine · 2022Article
- Characteristics and Prognosis of Antibody Non-responders With Coronavirus Disease 2019.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 4 countries.
Funding
Abstract
backgroundThe interplay between age and symptoms intensity on antibody response to SARS-CoV-2 infection has not been studied in a general population setting.
methodsWe explored the serologic profile of anti-SARS-CoV-2 antibodies after the first wave of the pandemic, by assessing IgG against the spike protein (ELISA-S), IgG against the nucleocapsid protein (ELISA-NP) and neutralizing antibodies (SN) in 82,126 adults from a French population-based multi-cohort study.
resultsELISA-S positivity was increased in 30- to 49-year-old adults (8.5%) compared to other age groups (5.6% in 20- to 29-year-olds, 2.8% in ≥ 50-year-olds). In the 3681 ELISA-S positive participants, ELISA-NP and SN positivity exhibited a U-shaped relationship with age, with a lower rate in 30- to 49-year-old adults, and was strongly associated with COVID-19-like symptoms.
conclusionOur study confirms the independent role of age and symptoms on the serologic profile of anti-SARS-CoV-2 antibodies, but the non-linear relationship with age deserves further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.